AQR Capital Management LLC Reduces Holdings in Pulmonx Co. (NASDAQ:LUNG)

AQR Capital Management LLC trimmed its holdings in shares of Pulmonx Co. (NASDAQ:LUNG) by 81.5% in the second quarter, HoldingsChannel reports. The firm owned 11,059 shares of the company’s stock after selling 48,671 shares during the period. AQR Capital Management LLC’s holdings in Pulmonx were worth $70,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Squarepoint Ops LLC grew its stake in Pulmonx by 261.2% in the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after acquiring an additional 104,432 shares during the period. Sei Investments Co. grew its stake in Pulmonx by 2.5% in the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after acquiring an additional 1,800 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Pulmonx by 7.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after acquiring an additional 69,595 shares during the period. XTX Topco Ltd purchased a new stake in Pulmonx in the 2nd quarter worth approximately $222,000. Finally, Renaissance Technologies LLC grew its stake in Pulmonx by 13.1% in the 2nd quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock worth $1,911,000 after acquiring an additional 34,800 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Stock Performance

Pulmonx stock opened at $6.50 on Friday. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $14.84. The company has a market capitalization of $252.30 million, a price-to-earnings ratio of -4.22 and a beta of 0.64. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. The firm’s fifty day moving average price is $7.29 and its 200 day moving average price is $7.38.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The firm had revenue of $20.78 million for the quarter, compared to the consensus estimate of $20.23 million. On average, research analysts forecast that Pulmonx Co. will post -1.64 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the sale, the director now owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the sale, the director now owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total transaction of $30,726.20. Following the sale, the insider now directly owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,351 shares of company stock valued at $231,094. Insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Canaccord Genuity Group lifted their target price on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company decreased their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.